{"title":"The hypoxia, lactate and lactylation axis in lung disease: A metabolic and epigenetic framework.","authors":"Mingxing Wu, Wenhui Xu, Yimin Zhu","doi":"10.1016/j.prp.2026.156741","DOIUrl":null,"url":null,"abstract":"<p><p>Hypoxia accompanies diverse pulmonary diseases and can promote glycolytic reprogramming and lactate accumulation. Lactate serves as a metabolic fuel and signalling molecule and can supply substrates for protein lysine lactylation. These activities are related but experimentally distinct. Here, we evaluate a hypoxia, lactate and lactylation framework across pulmonary hypertension, lung cancer, pulmonary fibrosis, acute lung injury, chronic obstructive pulmonary disease and asthma. We distinguish studies that manipulate oxygen availability and measure downstream metabolic and lactylation responses from those that demonstrate lactate signalling or lactylation without establishing hypoxia as the initiating event. We assess evidence for individual mechanisms according to human validation, biochemical resolution and the specificity of in vivo interventions. This comparison identifies substantial gaps between an observed metabolic sequence and proof that a particular lactylation event mediates disease. We also examine how protein lactylation intersects with RNA-modifying enzymes and DNA-repair machinery, while recognizing that direct nucleic-acid lactylation remains unvalidated. Potential interventions range from lactate production and transport to lactylation regulators, but current agents frequently alter metabolism or other protein acylations. The framework therefore provides a basis for testing how oxygen stress influences pulmonary pathology rather than evidence for a uniformly established causal pathway or a clinically validated therapeutic class.</p>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"289 ","pages":"156741"},"PeriodicalIF":3.7000,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology, research and practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.prp.2026.156741","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Hypoxia accompanies diverse pulmonary diseases and can promote glycolytic reprogramming and lactate accumulation. Lactate serves as a metabolic fuel and signalling molecule and can supply substrates for protein lysine lactylation. These activities are related but experimentally distinct. Here, we evaluate a hypoxia, lactate and lactylation framework across pulmonary hypertension, lung cancer, pulmonary fibrosis, acute lung injury, chronic obstructive pulmonary disease and asthma. We distinguish studies that manipulate oxygen availability and measure downstream metabolic and lactylation responses from those that demonstrate lactate signalling or lactylation without establishing hypoxia as the initiating event. We assess evidence for individual mechanisms according to human validation, biochemical resolution and the specificity of in vivo interventions. This comparison identifies substantial gaps between an observed metabolic sequence and proof that a particular lactylation event mediates disease. We also examine how protein lactylation intersects with RNA-modifying enzymes and DNA-repair machinery, while recognizing that direct nucleic-acid lactylation remains unvalidated. Potential interventions range from lactate production and transport to lactylation regulators, but current agents frequently alter metabolism or other protein acylations. The framework therefore provides a basis for testing how oxygen stress influences pulmonary pathology rather than evidence for a uniformly established causal pathway or a clinically validated therapeutic class.
期刊介绍:
Pathology, Research and Practice provides accessible coverage of the most recent developments across the entire field of pathology: Reviews focus on recent progress in pathology, while Comments look at interesting current problems and at hypotheses for future developments in pathology. Original Papers present novel findings on all aspects of general, anatomic and molecular pathology. Rapid Communications inform readers on preliminary findings that may be relevant for further studies and need to be communicated quickly. Teaching Cases look at new aspects or special diagnostic problems of diseases and at case reports relevant for the pathologist''s practice.